Vaccine Response to a Neo Polyssacharide Antigen Typhim Vi on the Identification of Secondary Immunodeficiencies in Hematological Malignancy

An increasing healthcare challenge in the management of hematological malignancy (HM) is secondary immunodeficiency (SID), either caused by the underlying malignancy or by treatments, including B-cell-targeting therapies. From January 2019, the EMA (European Medicines Agency) included the evaluation...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.3600-3600
Hauptverfasser:	Ochoa-Grullón, Juliana, Benavente Cuesta, Celina, Cordero Torres, G, Pérez López, Cristina, Peña Cortijo, Ascensión, Rodríguez de la Peña, Antonia, Álvarez Carmona, Ana, Mateo Morales, Marta, Rodríguez de Frías, Edgard, Guevara-Hoyer, Kissy, Fernández-Arquero, Miguel, Fernández-Paredes, Lidia, Perez de Diego, Rebeca, Sánchez-Ramón, Silvia
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!